$26.73
-0.78-2.84%
Últ. Act.: Oct 16, 6:24 PM
$26.40
-1.11-4.03%
Immunovant (IMVT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.52 | $-0.62 | $-0.71 | $-0.72 |
| Actual | $-0.75 | $-0.73 | $-0.61 | $-0.73 |
| Surprise | -44.2% | -17.7% | +14.1% | -1.39% |
| Revenue | ||||
| Estimate | — | — | $2.4M | — |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | — | — | -100.0% | — |
| Metric | Q2 '27E | Q3 '27E | Q4 '27E | Q1 '28E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.72 | $-0.68 | $-0.73 | $-0.70 |
| Revenue | ||||
| Consensus | — | — | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q1 | Aug 6, 2026 | $-0.75 | $-0.52 | -44.2 % |
| Q4 | May 20, 2026 | $-0.73 | $-0.62 | -17.7 % |
| Q3 | Feb 6, 2026 | $-0.61 | $-0.71 | 14.1 % |
| Q2 | Nov 10, 2025 | $-0.73 | $-0.72 | -1.39 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Feb 6, 2026 | $0 | $2.40M | -100.0 % |